Murray D Krahn, BA, MSc, MD

https://orcid.org/0000-0001-5836-397X
Dr. Murray Krahn is the Director of THETA (Toronto Health Economics and Technology Assessment Collaborative); F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto; Professor in the Faculties of Medicine and Pharmacy, University of Toronto; Senior Scientist at the Toronto General Hospital Research Institute; and Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto. He is also an attending physician in the division of General Internal Medicine at the University Health Network, Toronto. He completed a Master's Degree in Clinical Epidemiology at McMaster University, and a Clinical Fellowship in Medical Decision Making at the New England Medical Centre in Boston. Dr. Krahn's research program focuses on the use of decision analytic methods to examine health policy and health decision-making. He leads one of the leading technology assessment institutes in the country.
My central area of research interest has been the application of decision analysis and economic evaluation to broad questions of health and clinical policy. This methodologic focus has been expressed in a variety of content areas including prostate cancer and viral hepatitis. More recent interests include evaluating the role of disease specific utility assessment, using administrative data to build longitudinal cost models, and evaluating the role of health technology assessment in pharmaceutical reimbursement decisions.
Value Health Reg Issues. 2019 Nov 01;22:7-14
Welie AG, Gebretekle GB, Stolk E, Mukuria C, Krahn MD, Enquoselassie F, Fenta TG
J Viral Hepat. 2019 Oct 26;:
Sahakyan Y, Wong W, Yi Q, Thein HH, Tomlinson G, Krahn M
J Oncol Pract. 2019 Oct 24;:JOP1900061
Bremner KE, Yabroff KR, Coughlan D, Liu N, Zeruto C, Warren JL, de Oliveira C, Mariotto AB, Lam C, Barrett MJ, Chan KK, Hoch JS, Krahn MD
Cancer Invest. 2019 Nov 04;:1-11
Abrahamyan L, Huszti E, Bremner KE, Pechlivanoglou P, Mitsakakis N, Krahn M
Perit Dial Int. 2019 Nov-Dec;39(6):553-561
Krahn MD, Bremner KE, de Oliveira C, Dixon SN, McFarlane P, Garg AX, Mitsakakis N, Blake PG, Harvey R, Pechlivanoglou P
Liver Int. 2019 Sep 11;:
Erman A, Wong WWL, Feld JJ, Grootendorst P, Krahn MD
Value Health Reg Issues. 2019 Aug 27;19:138-144
Djalalov S, Djalalova D, Krahn M, Matveev N, Hoch JS
MDM Policy Pract. 2019 Jul-Dec;4(2):2381468319852594
Zoratti MJ, Zhou T, Chan K, Levine O, Krahn M, Husereau D, Clifford T, Schunemann H, Guyatt G, Xie F
Syst Rev. 2019 Aug 19;8(1):207
Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD
CMAJ. 2019 Jul 02;191(26):E733-E736
Krahn M, Bryan S, Lee K, Neumann PJ

Pages


Director of THETA (Toronto Health Economics and Technology Assessment Collaborative)
F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto
Professor in the Faculties of Medicine and Pharmacy, University of Toronto
Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto.